Exploring how a genetic variant affects Alzheimer's disease risk
Official title: Investigating the role of an EIF2B3 variant as an Alzheimer's disease risk modifier
Funded at Icahn School of Medicine at Mount Sinai · NIH-11054693 · Data updated 2026-11-12
This study is looking at how a certain gene might affect the risk of developing Alzheimer's disease, especially for people who have a specific gene variant called APOE4, to better understand how these genetic factors influence the progression of the disease.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 23, 2023 |
| Project end | March 22, 2026 |
| Funding year | 2025 |
| Award (this year) | $79,756 |
| NIH project number | 5F32AG082483-03 |
| Project ID | NIH-11054693 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who are APOE4 carriers and have a family history of Alzheimer's disease.
✕Less likely to help
Patients who do not carry the APOE4 variant or have no family history of Alzheimer's disease may not benefit from this research.
What this research studies
This research investigates the role of a specific genetic variant in the EIF2B3 gene and its potential to modify the risk of developing Alzheimer's disease, particularly among individuals who carry the APOE4 gene variant. By analyzing genetic data from individuals with varying ages of onset for cognitive impairment, the study aims to identify how this variant influences the severity and progression of Alzheimer's. The research employs genome-wide association studies to uncover genetic factors that may contribute to differences in clinical outcomes among APOE4 carriers.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and potentially new strategies for predicting and managing Alzheimer's disease risk in genetically susceptible individuals.
How similar studies have gone: Previous research has successfully identified genetic factors associated with Alzheimer's disease risk, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Garretti, Francesca — Icahn School of Medicine at Mount Sinai
- Study coordinator: Garretti, Francesca
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.